The Efficacy and Safety of JAK Inhibitor in the Treatment of Anti-MDA5 Antibody-positive Dermatomyositis Patients
Condition: Dermatomyositis, Adult Type Intervention: Drug: JAK Inhibitor Sponsor: First Affiliated Hospital Xi'an Jiaotong University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 19, 2021 Category: Research Source Type: clinical trials
